Trial Profile
A phase 1 trial of lirilumab in combination with nivolumab in patients with hematological cancers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Feb 2015
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Cancer; Haematological malignancies
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 Feb 2015 New trial record